Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Integration of Biovail Nearly Completed, Valeant Looks For More Deals In 2011

This article was originally published in The Pink Sheet Daily

Executive Summary

Valeant's price-conscious, opportunistic approach to business development and relentless pace of activity has enabled it to quadruple sales in three years and grow its top-line 7% in 2010.
Advertisement

Related Content

The Quintessential Specialty Pharma, Valeant Embodies PE Tenets
Back In Biotech, Waksal's Kadmon Emerges From Stealth Mode To Focus on Hep C
Tax Benefits Highlight Announced Merger Of Valeant And Biovail
Tax Benefits Highlight Announced Merger Of Valeant And Biovail

Topics

Advertisement
UsernamePublicRestriction

Register

PS071693

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel